MedTrace Logo

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

NCT06258642 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-08-20

No results posted yet for this study

Summary

This study is a single arm, multi-center, prospective clinical trial. The purpose of this study is to evaluate the efficacy and safety of liposomal irinotecan combined with anlotinib hydrochloride for relapsed small-cell lung cancer, who have progressed on or less than 6 month after platinum-based first-line therapy.

Conditions

  • Small Cell Lung Cancer Recurrent

Interventions

DRUG

Irinotecan Liposome

70 mg/m\^2 , d1, Q2W, iv

DRUG

Anlotinib

12 mg, qd, po for 2 consecutive weeks and then discontinued for 1 week.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Jialei Wang, Doctor · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-17
Primary Completion
2026-04-30
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06258642 on ClinicalTrials.gov